Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a Healthcare company (Biotechnology) with a market capitalization of $487M. The Maz Rating grades it against the other companies in its sector.
Capricor Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.41, Capricor Therapeutics, Inc. trades at 2.4x book value, with an EV/EBITDA of 0.5. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -56.7%, return on invested capital of -50.8% and a free cash flow yield of -29.5%. On the balance sheet: a debt-to-equity ratio of 0.44 and a current ratio of 6.77. Over the past 52 weeks the share price ranged from $2.96 to $40.37, with a beta of 0.53.
Capricor Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 9 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Capricor Therapeutics, Inc. (CAPR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 41.6% / 30% · Interest income / Revenue 202588600.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 41.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 202588600.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 41.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 202588600.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.78% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 74.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 202588600.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 59.8% / 33.33% · (Cash+Recv) / Total Assets 59.8% / 33.33% · Interest income / Revenue 202588600.0% / 5% | Fail |
No. As of September 2026, Capricor Therapeutics, Inc. (CAPR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Capricor Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 202588600.0% of each dividend: Capricor Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.